You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
ICU-CARE: An interactive mobile app to enhance the efficiency of daily informal caregiving in the intensive care unit
SBC: SILICON CURES LLC Topic: NINRPROJECT SUMMARY Actively involving informal caregivers in direct patient care at the bedside in the intensive care unit (ICU) has the potential to improve patient, informal caregiver, and health care system outcomes. Practice guidelines call for the liberal inclusion of informal caregivers as active partners in ICU care, but there is a critical, unmet need to develop tools that effectively operati ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Assessment of Deep Learning Classification Methods for Parkinsonism
SBC: AUTOMATED IMAGING DIAGNOSTICS LLC Topic: 108SUMMARY The growth rate in the number of people diagnosed with Parkinsonism is substantial. Estimates indicate that from 1990 to 2015 the number of Parkinsonism diagnoses doubled, with more than 6 million people currently diagnosed. By 2040, there will be between 12-14 million people diagnosed with Parkinsonism. Parkinson’s disease (PD), multiple system atrophy Parkinsonian variant (MSAp), and p ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
MT-125 for the Therapeutic Treatment of Glioblastoma
SBC: MYOSIN THERAPEUTICS INC. Topic: 102PROJECT SUMMARYAn area of significant unmet need is the treatment of glioblastoma (GBM), an aggressive, fast-growing and lethal brain cancer that represents 48% of all malignant brain tumors. Untreated, GBM is fatal within three months, and due to its high rate of recurrence and invasive nature, the current standard of care, consisting of safe maximal tumor resection, radiation therapy and chemoth ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Protection of transplanted heart function by regulation of Na/K pump activity
SBC: WR Biotech, LLC Topic: NHLBIThe objective of this proposal is to examine a novel technique called improved Synchronization Modulation Electric Field (i-SMEF) in the protection of donor hearts and improvement of transplanted graft functions. We will apply the i-SMEF on donor hearts during static cold storage and evaluate the transplanted graft function following heart transplantation in mice.Heart transplantation (HTx) remain ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Human specific STING agonists for the treatment of cancer
SBC: STINGINN, LLC Topic: 102PROJECT SUMMARY Cellular innate immune sensors, such as STING (STIMULATOR OF INTERFERON GENES), have evolved to detect microbial infection of the cell (1-3). STING controls the potent cytosolic DNA-stimulated innate immune pathways and is activated by cyclic dinucleotides (CDNs) such as cyclic di-GMP and cyclic-di-AMP secreted by intracellular bacteria following infection. Alternatively, STING can ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Optimizing Small Molecule Mechanomimetics to Treat Age-related Osteoporosis.
SBC: OAK RIDGE THERAPEUTIC DISCOVERY LLC Topic: NIAAbstract There is an unmet need to develop treatments for senile osteoporosis, a disorder characterized by an age-related reciprocal decrease in osteogenesis and increase in bone marrow fat. Senile osteoporosis resembles disuse osteopenia, suggesting its pathogenesis involves impaired bone mechanosensing. We discovered that the polycystin heterotrimeric complex (1PC1+3PC2) functions as a mechanose ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Developing a selective TRPC3 ion channel inhibitor for epilepsy treatment
SBC: SEAK Therapeutics, LLC Topic: 106Project SummaryEpilepsy is one of the most common brain disorders. Current drugs have limited efficacy. Identifying new targeted drugs that can be used as safer, more effective therapies is in urgent unmet need. Selective inhibition of the transient receptor potential canonical 3 (TRPC3) emerges as a novel strategy to impede epilepsy. However, the currently best selective TRPC3 inhibitor, Pyr3, ha ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Simple Method for Screening of HIV Drug Resistance in Resource-Limited Settings
SBC: Discidium Biosciences, LLC Topic: NIAIDAbstract Drug resistance to antiretroviral therapy for HIV infection is a serious clinical problem without cost-effective solutions in low and middle-income countries (LMICs) where standard genotypic resistance assays are unaffordable. Discidiumandapos;s goal is to develop a single tube assay that uses lyophilized reactants, standard PCR and in-tube readout, that can be used as a screening resista ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Cell permeant peptidomimetics to prevent delayed vasospasm and neurological deficits after subarachnoid hemorrhage
SBC: VasaMetrix Topic: 107PROJECT SUMMARYSubarachnoid hemorrhage (SAH) due to rupture of an intracranial aneurysm leads to delayed vasospasm resulting in neuroischemia (stroke). The overall morbidity (profound neurologic deficit in 10-20% of survivors) and mortality (50%) are high, and the disease affects a relatively young adult population. Therapeutic options to prevent delayed vasospasm and neuroischemia after SAH are c ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Development of Natural Killer (NK) Cell Line-Derived Extracellular Vesicles as a New Treatment for Cancer
SBC: Vanquish Bio LLC Topic: NCIVanquish Bio is an immunotherapy company reimagining treatment of cancer with the use of unique natural killer (NK) cell derived extracellular vesicles (EVs). The goal of this STTR is to develop a therapy using natural products of the immune system for targeted destruction of myeloma tumor cells. Multiple myeloma (MM) represents ~10% of hematological cancers, and there were ~32,110 new cases and ~ ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health